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Abstract
Background: Antibiotics are a mainstay of treatment for bacterial infections worldwide, yet the effects of typical
antibiotic prescriptions on human indigenous microbiota have not been thoroughly evaluated. We examined the
effects of the two most commonly prescribed antibiotics (amoxicillin and azithromycin) in the USA to discern
whether short-term antibiotic courses may have prolonged effects on human microbiota.
Results: We sampled the feces, saliva, and skin specimens from a cohort of unrelated, cohabitating individuals over
6 months. An individual in each household was given an antibiotic, and the other a placebo to discern antibiotic
impacts on microbiota, as well as determine whether antibiotic use might reshape the microbiota of each household.
We observed household-specific patterns of microbiota on each body surface, which persevered despite antibiotic
perturbations. While the gut microbiota within an individual became more dissimilar over time, there was no
evidence that the use of antibiotics accelerated this process when compared to household members. There
was a significant change in microbiota diversity in the gut and mouth in response to antibiotics, but analogous
patterns were not observed on the skin. Those who received 7 days of amoxicillin generally had greater reductions in
diversity compared to those who received 3 days, in contrast to those who received azithromycin.
Conclusions: As few as 3 days of treatment with the most commonly prescribed antibiotics can result in
sustained reductions in microbiota diversity, which could have implications for the maintenance of human
health and resilience to disease.
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Background
The human body has many different surfaces and each
is home to its own unique microbes [1], including cellu-
lar microbes (e.g., bacteria, archaea, and fungi) as well as
large populations of viruses [2–6]. These microbes are
collectively referred to as “the human microbiome,” and
a litany of studies exist examining those microbes and
their contributions to the maintenance of health and the
development of disease [7–10]. Many microbiome stud-
ies focus on gut bacterial biota, which have been shown
to be altered in conditions such as obesity [11–13],
diabetes [14], and inflammatory bowel diseases [7, 15],
and potentially may play roles in disorders of neurological
development [16]. Host genetic factors, geography, and
environmental variables (e.g., sex and hormonal fluctua-
tions) have also been linked to microbes and their relative
abundances in the human microbiome [17–22]. How hu-
man microbial communities respond to perturbations
such as antibiotics, and whether such perturbations affect
host susceptibility to disease, have become cornerstones
of human microbiome research.
Microorganisms such as bacteria, fungi, viruses, and
parasites cause many of the world’s diseases, yet only
bacterial infections are usually susceptible to treatment
with commonly prescribed antibiotics. The US Centers
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for Disease Control estimates that up to 50 % of pre-
scribed antibiotics in the USA are unnecessary, and 30 %
of those are prescribed for outpatients [23]. Their use
has been associated with the emergence of antibiotic re-
sistance, which resulted in an estimated 23,000 deaths in
2013. The Institute for Healthcare Informatics Review
indicates that the two most overused antibiotics in the
USA include azithromycin (56.3 million prescriptions
annually in 2011) and amoxicillin (53.8 million prescrip-
tions annually in 2011), compared to a population size
of only 311.7 million in 2011. Despite the widespread
use of azithromycin and amoxicillin, many studies char-
acterizing the effects of antibiotics on the microbiome
focus on other antibiotics such as clindamycin and cip-
rofloxacin [24, 25]. This focus in some cases is related to
the commonly known effects of these drugs on human
gut microbes, with ciprofloxacin having broad activity
against Proteobacteria that inhabit the gut, and clinda-
mycin known to alter gut microbiota in a manner that is
closely associated with colonization and subsequent dis-
ease caused by Clostridium difficile [26, 27]. Very little is
known about the effects of the azithromycin and amoxi-
cillin (typically given in short 3- to 7-day courses) on the
microbiota of human body surfaces, and whether their
effects may be sustained over long time periods.
It has been established that cohabitating individuals
share bacterial biota [28, 29]; however, in many of
these studies, the cohabitating individuals had some
genetic relationships. For example, monozygotic and
dizygotic twins share a substantial proportion of their
bacterial biota [21, 30], but do not necessarily need
to cohabitate to have similarities in their microbiota.
This phenomenon suggests that both proximity and
host genetic factors contribute to the composition of
the human microbiome. The sharing of microbiota
between close contacts gains greater importance when
considering that our microbiomes may carry antibiotic re-
sistance [31, 32]. The potential for sharing antibiotic-
resistant organisms in our microbiomes that may not be
causing disease but could cause disease under certain cir-
cumstances is a growing public health concern. How or
whether the sharing of our microbiota may be affected by
the use of antibiotics has not previously been examined,
as there may also be collateral effects of antibiotic use in
an individual for their close contacts.
In this study, we recruited a cohort of 56 genetically
unrelated individuals, with 48 of them living in pairs in
24 separate households. In each household, 1 individual
took 3 to 7 days of an antibiotic and the other took 3 to
7 days of a placebo. Our goals were to (1) discern the
effects of the 2 most commonly prescribed antibiotics
on the microbiota of the skin, gut, and mouth, (2)
characterize the degree of similarity in the microbiota of
unrelated household contacts and decipher whether it is
significantly affected by antibiotic use, (3) characterize
the long-term effects of typical antibiotic prescriptions
on microbiota diversity, and (4) discern whether there
may be collateral effects to antibiotic use for the diver-
sity of microbiota in household contacts.
Results
Study cohort
We recruited and sampled the feces, saliva, and skin
from a cohort of 56 subjects over a 6-month period from
the University of California, San Diego, campus. Of
those 56 individuals, there were 24 separate households
consisting of 2 individuals and 8 separate controls not
enrolled with a housemate (Fig. 1). In each household, 1
individual received treatment with an antibiotic (amoxi-
cillin or azithromycin), and the other individual received
treatment with a placebo (vitamin C). Twelve house-
holds received amoxicillin, with 6 households receiving
3 days and another 6 receiving 7 days of therapy. In
these households, amoxicillin was given twice daily and
the placebo also was given twice daily. Another 12
Fig. 1 Flowchart of study design
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households received azithromycin, with 6 receiving
3 days and the other 6 receiving 7 days of therapy.
The azithromycin was given once daily in these
households, and the placebo was given once daily as
well. The additional 8 subjects enrolled in the study
were not enrolled with a housemate and did not re-
ceive antibiotic or placebo. Households were random-
ized into the separate arms of the study; however, the
study subjects were not blinded because we had to
account for existing drug allergies and medication in-
teractions in our decisions to give them antibiotics.
Study subjects were sampled on day 0 (day prior to
antibiotics), day 3 (on the third day of antibiotics),
day 7, week 8, and at 6 months.
There were no significant differences identified in
the demographics of the subjects enrolled in the
amoxicillin arm, azithromycin arm, or control arm of
the study (Table 1). The mean age of subjects was 24
in the amoxicillin arm, 29 in the azithromycin arm,
and 25 in the control arm. Approximately 50 % of
the study participants were female, and none of the
study subjects had taken systemic antibiotics for a
year prior to the initiation of the study. The subjects
lived together ranging from 1 to 54 months prior to
the initiation of this study, and 58 % in the amoxicil-
lin arm were romantic couples compared to 50 % in
the azithromycin arm. The majority of study partici-
pants were Caucasian (54 %), with roughly equal
numbers of Latino (25 %) and Asian subjects (21 %)
(Additional file 1: Table S1). Five of the 24 households
(2 in amoxicillin arm and 3 in azithromycin arm) were lost
to follow-up after the 8-week time point and did not
complete the 6-month time point.
Household-specific patterns in the mouth, gut, and skin
We sequenced the V1–V2 hypervariable segment of
the 16S rRNA gene from the feces, saliva, and skin of
all subjects at all time points in the study to
characterize the bacterial biota present on each body
surface with a total of 806 specimens (269 feces, 270
saliva, and 267 skin). Because previous studies that
demonstrate household-specific patterns of bacterial
biota are confounded by genetically related individuals
living in those households [28, 29], we tested whether
there were household-specific patterns in the bacterial
biota among the genetically unrelated individuals in
this cohort. By measuring weighted UniFrac distances
[33] between household pairs longitudinally and com-
paring with individuals from separate households, we
found smaller distances among the household pairs,
which was statistically significant (p < 0.05) in the gut,
saliva, and skin for all households (Additional file 2:
Figure S1). When comparing household pairs with
control subjects who were not enrolled with house-
mates, the distances were also significantly smaller in
the gut and saliva, but not on the skin. The smaller
distances indicate a higher degree of similarity among
taxa and their relative abundances. The similarity ob-
served in the bacterial biota was not significantly affected
by the use of antibiotics, as the same patterns were ob-
served in households that received azithromycin and those
that received amoxicillin (Fig. 2). Additionally, the dis-
tances between subjects in each household was not signifi-
cantly altered on any body surface over the course of the
study (Additional file 2: Figure S2), suggesting that the use
of antibiotics did not substantially change the collective
microbiota of the household.
We measured weighted UniFrac distances among the
households based on whether the individuals in the
households were romantic couples or roommates to dis-
cern whether personal relationships significantly shape
the shared microbiota within the household. We found
that in all households, there was a statistically significant
pattern of shared microbiota (p < 0.05 in each case; data
not shown); however, there was no significant relation-
ship identified in the feces, saliva, or skin based on
whether the individuals were couples or roommates.
There was a trend toward more shared taxa in couples,
but the trend was not statistically significant on any
body surface (Additional file 2: Figure S3 and S4).
Effects of time on microbiota compositions
We evaluated whether microbiota compositions within
subjects were becoming more dissimilar over time, and
Table 1 Demographics of study participants
Characteristics Amoxicillin arm (N = 24) Azithromycin arm (N = 24) Control arm (N = 8)
Age (years)¥ 24 ± 3.4 29 ± 13 25 ± 11
Female sex (%) 54 45 50
No. subjects with antibiotic consumption within last year 0 0 0
No. subjects with antibiotic consumption within last 3 years (%) 8 (33) 9 (37.5) 2 (25)
No. households who are couples (%) 7 (58) 6 (50) NA
Approximate time living together prior to study (months) 16 (range 3 to 54) 16 (range 1 to 42) NA
Plus-minus values indicate mean ± standard deviation
¥ No significant differences among groups by ANOVA
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whether the use of antibiotics may accelerate this
process. We measured weighted UniFrac distances be-
tween day 0 (day prior to antibiotics or placebo) and
each subsequent time point to identify whether the
degree of dissimilarity increased over time. In the gut,
the microbiota of subjects taking amoxicillin and azi-
thromycin generally grew more dissimilar over each
time point measured (Fig. 3). While these data were
not statistically significant, a clear trend could be ob-
served for most time points. For those subjects taking
placebo, the exact same trend was identified. This
trend was not a direct result of the placebo or anti-
biotic therapy, as those control subjects who received
no treatment also demonstrated the same trend. The
Fig. 2 Bar graph representing mean weighted UniFrac distances (±standard error) within a household (white bars) and between different households
(gray bars) based on the antibiotic received in each household. The y-axis represents mean weighted UniFrac distances, while the body site sampled
and antibiotic received within each household is represented on the x-axis. p values were determined using the Mann Whitney U test
Fig. 3 Bar graph (±standard error) representing the mean weighted UniFrac distances from day 0 in the feces of all subjects over time. The y-axis
represents mean weighted UniFrac distances, and the x-axis represents the different subject groups over time based on the therapy they received. D3
represents day 3, D7 represents day 7, W8 represents week 8, and M6 represents month 6. p values were determined using the Kruskal Wallis test
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magnitude of the dissimilarity among the different anti-
biotic, placebo, and control groups did not differ signifi-
cantly. These data suggest that while the gut microbiota
grow more dissimilar within a subject over time, the use
of short courses of common antibiotics does not signifi-
cantly accelerate the process. No similar trends were iden-
tified in the mouth (Additional file 2: Figure S5) or on the
skin (Additional file 2: Figure S6), suggesting that the gut
is unique among these body surfaces in the evolution of
its microbial communities.
Taxonomic responses to antibiotics
We examined the taxonomic compositions of all sub-
jects across the different body surfaces over time to
decipher whether there were differences attributable
to the antibiotics. We first measured beta diversity
within and between all subjects and visualized the
output using principal coordinates analysis (Fig. 4).
Most of the samples reflected the body site from
which they were derived and could not be distin-
guished based on whether or not the subject received
an antibiotic or placebo.
In the gut, the most abundant taxa identified
belonged to families Bacteroidaceae, Lachnospiraceae,
and Ruminococcaceae. In both the azithromycin and
amoxicillin arms of the study, the abundance of Lach-
nospiraceae was significantly diminished after anti-
biotic therapy and remained diminished at 6 months
(Additional file 2: Figure S7). We compared the taxa
from each individual taking antibiotics with their
housemate taking a placebo to decipher whether there
were taxa in each household whose relative abun-
dance was altered as a response to the antibiotics.
Lachnospiraceae were significantly diminished (p ≤ 0.01)
in response to amoxicillin on days 3 and 7 in most
households, but their relative abundances increased
significantly in comparison to their housemates by
week 8 (Fig. 5). Veillonellaceae, Bacteroidales, and
Porphyromonadaceae (anaerobic bacteria) were signifi-
cantly decreased in response to amoxicillin, while
Fusobacteriaceae (also anaerobes) were increased. Bifi-
dobacteriales and Erysipelotrichaceae were initially de-
creased, and subsequently increased in comparison to
their housemates taking placebo. In response to azithro-
mycin therapy, Erysipelotrichaceae, Veillonellaceae, and
Clostriales were significantly diminished, while Alcaligen-
aceae were increased compared to their housemates.
In the saliva, the most abundant taxa identified were
Prevotellaceae, Streptococcaceae, Veillonellaceae, and
Neisseriaceae (Additional file 2: Figure S7). In response
to amoxicillin, Veillonellaceae, Actinomycetaceae, Neis-
seriaceae, Prevotellaceae, and Porphyromonadaceae were
all significantly increased in comparison to their house-
mates, while Streptococcaceae and Gemellaceae were
diminished (Fig. 5). In response to azithromycin, Bifido-
bacteriales and Veillonellaceae were increased, while Clos-
tridiales, Neisseriaceae, and Erysipelotrichaceae were
diminished in comparison to their housemates.
On the skin, the most abundant taxa identified were Cor-
ynebacteriaceae, Propionibacteriaceae, Staphylococcaceae,
and Streptococcaceae (Additional file 2: Figure S7). In re-
sponse to both amoxicillin and azithromycin, the relative
abundances of Streptococcaceae, Staphylococcaceae,
Actinomycetales, Corynebacteriaceae, and Propionibac-
teriaceae were all altered in comparison to their
housemates (Fig. 5).
Fig. 4 Principal coordinates analysis of beta diversity present in all subjects, time points, and sample types based on whether they received
antibiotics (amoxicillin or azithromycin) or placebo
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Reduction in microbial diversity
We characterized the diversity of the microbial commu-
nities on each body surface in response to antibiotics to
decipher whether diversity was substantially impacted
longitudinally by the use of typical antibiotic courses.
We first examined changes in microbiota diversity in
each subject compared to their housemate taking a pla-
cebo. In the gut, we found that there was a significant
reduction in diversity compared to their housemates for
subjects taking amoxicillin (Fig. 6a). While there was a
trend toward a sustained reduction in microbiota diver-
sity compared to their housemates at 8 weeks and
6 months, the data were not statistically significant. Re-
ductions in diversity were observed in subjects taking
only 3 days of amoxicillin, but they were generally less
than those observed in subjects who took 7 days of
amoxicillin. Similar results were identified when com-
paring subjects who took azithromycin with their house-
mates. At 3 and 7 days, significant reductions in gut
microbial diversity was observed, but this reduction was
not sustained throughout the study (Fig. 6b). There
were no significant differences observed between
subjects who took 3 or 7 days of azithromycin. We
also analyzed reductions in gut diversity in subjects
who took amoxicillin and azithromycin and compared
to control subjects rather than their housemates
(Fig. 7a). We found that there was a substantial re-
duction in microbiota diversity in subjects who took
either amoxicillin or azithromycin and that those re-
ductions were sustained throughout the 6-month
study. Interestingly, we also identified reductions in
the diversity of their housemates, which was not ob-
served in control subjects. When examining changes
in diversity time point by time point, the majority of
the diversity reductions occurred within the first 3 days of
antibiotic therapy (Additional file 2: Figure S8).
We also compared changes in oral microbiota diver-
sity between the subjects within a household. We iden-
tified reductions in microbiota diversity in subjects
taking amoxicillin compared to their housemates, but
most reductions were not statistically significant
(Fig. 8a). As was found in the gut, there were generally
greater reductions in microbiota diversity in response
to 7 days of amoxicillin than were observed after just
Fig. 5 Heatmaps representing the relative abundances of taxa in individuals taking antibiotics that were significantly different when compared
to their housemates receiving placebo. Each individual taking an antibiotic is shown next to their housemate taking a placebo. Each household
consisting of two subjects is separated by gray vertical boxes. a Feces, b saliva, and c skin. The family or order for each OTU shown on the
heatmaps is shown to the right of each heatmap, and the antibiotic received is shown to the left of each heatmap. The index color scale is
shown below
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3 days. In response to azithromycin, we found signifi-
cant reductions in microbiota diversity after both 3 and
7 days of therapy, but those reductions were not sus-
tained by week 8 (Fig. 8b). We also examined reduc-
tions in microbiota diversity independent of their
housemates, and found that there were sustained re-
ductions in microbiota diversity in response to amoxi-
cillin over the entire 6 months of the study, but that
reductions in diversity in response to azithromycin
were not sustained (Fig. 7b). Unlike the reductions in
microbiota diversity in the guts of housemates who
took a placebo, there were no significant diversity
reductions in the oral microbiota of housemates. The ma-
jority of the diversity reductions that took place in re-
sponse to antibiotics occurred within the first 3–7 days of
therapy (Additional file 2: Figure S8).
When compared to housemates, subjects who received
amoxicillin saw a reduction in their cutaneous micro-
biota diversity after 3 days, but not in response to azi-
thromycin (Additional file 2: Figure S9). Independent of
their housemates, this reduction in microbiota diversity
in response to amoxicillin was sustained over the
6 months of the study (Fig. 7c). We also observed a re-
duction in diversity of the subjects who received the pla-
cebo, which was greater than that observed in response
to antibiotics. The reduction in microbiota diversity ob-
served in response to amoxicillin occurred within the
first 3 days of therapy (Additional file 2: Figure S8).
Discussion
We sought to elucidate the effects of the most com-
monly prescribed antibiotics in the USA on the micro-
biota of human body surfaces. Because antibiotics often
are absorbed across the GI tract and distributed to the
tissues via the bloodstream, we expected that each would
affect the microflora of each body surface tested. Both
amoxicillin and azithromycin often are prescribed un-
necessarily, and their effects on the microbiota of each
body surface may have implications for resilience to
pathogen colonization and susceptibility to disease. We
found that each antibiotic had significant impacts upon
the microbiota of the mouth and gut that were apparent
after only 3 days of therapy (Additional file 2: Figure S8).
Other studies have demonstrated that lesser prescribed
antibiotics such as ciprofloxacin, clindamycin, and mino-
cycline also can have profound and lasting effects on the
microbiota of the gut [24, 25].
Bacterial biota can be shared between individuals in a
household, and those household-specific patterns ob-
served on body surfaces also extend to household sur-
faces such as floors and doorknobs [29]. We did not
recruit any subjects with known genetic relationships in
an attempt to avoid confounders that may result in simi-
lar microbiota between individuals. On all body surfaces
studied, we could identify household-specific patterns
using weighted UniFrac distances, which take into ac-
count both the presence of taxa and their relative abun-
dances. When this same analysis was performed using
unweighted distances that do not account for relative
abundances, the data were no longer significant (data
not shown), which suggests that relative abundances of
taxa on various body surfaces are influenced by the
household environment. Unfortunately, the individuals
in this study had been cohabitating for various time pe-
riods prior to the initiation of this study, so the rapidity
with which these household-specific patterns developed
Fig. 6 Bar graphs (±standard error) representing the normalized
difference in Shannon diversity in the gut between individuals
taking antibiotics and their housemates taking placebo at each time
point studied. a Households that took amoxicillin and placebo and
b households that took azithromycin and placebo. All households
collectively are represented by the blue bars, households that took
3 days of an antibiotic are represented by red bars, households that
took 7 days of an antibiotic are represented by green bars, and control
subjects who were not enrolled with housemates and are represented
by purple bars. The x-axis represents the time point and the y-axis
represents the change in normalized change in Shannon diversity
since the prior time point. Negative results indicate lower diversity in
the subjects taking antibiotics compared to their housemates
taking placebo, and positive results indicate greater diversity in
the housemates taking placebo compared to the individuals
taking antibiotics. For the control subjects, the bars represent the
mean change in diversity among all control subjects. p values were
determined using the Mann Whitney U test, and *p values ≤0.05
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could not be assessed. We also identified a trend of
greater similarity among the microbiota of romantic
couples compared to roommates, similar to that which
has previously been described in the oral cavities of cou-
ples [34]. While we did not record information on phys-
ical contact between housemates, we believe the greater
similarity in microbiota among romantic couples
reflected greater physical contact. Despite the substantial
conservation of the gut microbiota within subjects and
households over time, genetic distances increased over
time within each subject [35], indicating that there was
some turnover of gut taxa and/or sustained alterations
in their relative abundances over time. Interestingly, this
trend did not appear to be accelerated by the use of anti-
biotics (Fig. 3), which suggests that this trend would
have taken place even without the interventions that
took place in this study.
By studying the two most commonly prescribed an-
tibiotics in the USA, we wanted to identify whether
there were sustained effects of common antibiotic
treatments on the human microbiome. Our use of
multiple controls allowed for us to discern whether
microbiota diversity was significantly impacted com-
pared to close contacts and to strangers. Because the
external controls were not enrolled in the study with
housemates and did not receive either antibiotic or
placebo, we believe that they provided the most reli-
able reference group with regard to microbiota vari-
ation over time. We found separate trends in our
study depending on which controls we used, which
highlights that there may be collateral effects to anti-
biotic use for our close contacts. For example, there
were significant diversity reductions in gut microbiota
in response to amoxicillin and azithromycin compared
to close contacts, but those reductions were not sus-
tained after 8 weeks (Fig. 6). This trend largely
reflects the concomitant reduction in gut microbiota
diversity that is observed in the housemates of those
taking antibiotics that was not identified in the other
control subjects (Fig. 7). We originally hypothesized
that we would observe an increase in gut microbiota
diversity due the sharing of microbiota with house-
mates and did not predict that we would observe di-
versity reductions in the housemates. These data
suggest that the influence of close contact on an indi-
vidual’s microbiome may extend beyond simply shar-
ing microbes and may indicate that there is a balance
in microbe sharing that contributes to diversity.
We observed different responses of host microbiota
based on both the antibiotic used and the length of
therapy. While these antibiotics are known to have dif-
ferent spectrums of activity against microbes, they also
differ significantly in their half-life, which might result
in different effects on our microbiota. Amoxicillin has a
half-life of 1 h, while azithromycin has a half-life of
68 h. Thus, we might expect the effects of shorter
courses of azithromycin to have similar effects as longer
courses because the drug will remain in the host for an
extended period regardless of whether the subject re-
ceives a 3- or a 7-day course. This is what we observed
in both the feces and saliva of subjects taking azithro-
mycin (Figs. 6b and 8b ). We observed the opposite
trend in subjects taking amoxicillin. Because the drug is
eliminated from subjects much more rapidly, we believe
that we observed more profound effects on diversity in
those taking a 7-day course than in those taking a 3-day
course (Figs. 6a and 8a).
Prior to this study, we believed that the use of these
common antibiotics would accelerate microbiota
changes significantly over 6 months. We found that
the subjects who took antibiotics were no less similar
to their original state than were subjects who took
Fig. 7 Bar graphs (±standard error) representing the change in Shannon diversity from day 0 across time in each subject group by body site
tested. a Feces, b saliva, and c skin. Groups that received antibiotics, placebo, or no therapy (controls) are labeled across the x-axis, and the y-axis
represents the change in Shannon diversity. *p values <0.05 using the Mann Whitney U test comparing subject groups at specified time points
with the controls
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placebo or no therapy at all (Fig. 3 and Additional file 2:
Figure S5 and S6). We did, however, identify changes in
microbiota diversity that did not recover to baseline re-
gardless of the antibiotic taken (Fig. 7). We did not follow
the subjects beyond 6 months, so we cannot rule out the
possibility that the differences we observed in diversity
after just 3 to 7 days of antibiotics could render these sub-
jects more susceptible to pathogen colonization.
Similar to a prior study, there was a near complete re-
covery of microbial diversity in the saliva [25] regardless
of the antibiotic that was used (Fig. 7b). In that study,
minocycline, amoxicillin, clindamycin, and ciprofloxacin
were used and each showed a similar trend. We utilized
a placebo in this study to simulate the model of a clinical
trial and initially intended for the study to be blinded.
We unblinded the study because many of the study par-
ticipants were taking oral contraceptives, which would
interact with azithromycin. The placebo (vitamin C)
could have affected the microbiota of the skin, as the
subjects who received vitamin C had substantial diversity
decreases in their skin microbiota (Fig. 7c). Because vita-
min C is rapidly excreted when high plasma levels are
reached, we did not expect to observe significant micro-
biota changes after only 3 to 7 days of placebo.
Conclusions
Our data help to illustrate important concepts regarding
the responses of our microbiota to common antibiotic
perturbations. The shared microbiota in the gut, mouth,
and on the skin of close contacts who were not known
to be genetically related bolsters the concept that genetic
relationships are not required to share our microbiota.
We believe that the close contact and shared environ-
mental reservoirs resulted in the sharing of microbiota
within the households; however, there are other con-
founders which could also affect the relative proportions
of shared microbiota within a household. For example,
14 of the 24 households studied had pets including dogs,
cats, fish, and hamsters (Additional file 1: Table S1),
which may also have served as vehicles for the sharing
of microbiota. We recorded specific details regarding
diet preferences for each subject studied, but did not
note any differences between the subject groups that
might account for the microbiota differences observed
(data not shown). Only two of the subjects studied were
vegetarians (Additional file 1: Table S1), but their micro-
biota was more similar to their housemates than to each
other. The impact of short typical antibiotic courses per-
sisted for at least 6 months in the gut, a factor that
should be taken into account whenever antibiotics are
prescribed. While our cohort was not followed nearly
long enough to ascertain whether there may be risks to
the sustained diversity reductions, the concomitant re-
ductions in diversity observed in housemates suggests
that antibiotic prescriptions may pose collateral risks to
our close contacts.
Methods
Cohort design
Forty-eight subjects were enrolled in the study in pairs,
with 2 individual living in each household. An additional
8 individuals were enrolled without a housemate and re-
ceived no therapy over the course of the 6-month study.
Households were randomized into either the amoxicillin
or azithromycin arms of the study. Those subjects also
were randomized to receive either antibiotic or placebo;
Fig. 8 Bar graphs (±standard error) representing the normalized
difference in Shannon diversity in the saliva between individuals
taking antibiotics and their housemates taking placebo at each time
point studied. a Households that took amoxicillin and placebo and
b households that took azithromycin and placebo. All households
collectively are represented by the blue bars, households that took
3 days of an antibiotic are represented by red bars, households that
took 7 days of an antibiotic are represented by green bars, and
control subjects who were not enrolled with housemates and are
represented by purple bars. The x-axis represents the time point and
the y-axis represents the change in normalized change in Shannon
diversity since the prior time point. Negative results indicate lower
diversity in the subjects taking antibiotics compared to their
housemates taking placebo, and positive results indicate greater
diversity in the housemates taking placebo compared to the
individuals taking antibiotics. For the control subjects, the bars
represent the mean change in diversity among all control subjects.
p values were determined using the Mann Whitney U test, and
*p values ≤0.05
Abeles et al. Microbiome  (2016) 4:39 Page 9 of 12
however, because of the large numbers of penicillin aller-
gies reported (Additional file 1: Table S1) and subjects
using oral contraceptives (interact with azithromycin),
some subjects who were randomized to receive antibi-
otics were given the placebo, while their housemate re-
ceived the antibiotic instead. Of the household pairs, 6
pairs were placed into the 3-day amoxicillin arm, 6 pairs
were placed into the 7-day amoxicillin arm, 6 pairs were
placed into the 3-day azithromycin arm, and 6 pairs
were placed into the 7-day azithromycin arm (Fig. 1). In
each household, 1 subject received either 3 or 7 days of
an antibiotic and the other subject received either 3 or
7 days of the placebo (vitamin C). The dose of amoxicil-
lin was 500 mg twice daily, and the dose of vitamin C
was 500 mg twice daily. The dose of azithromycin was
500 mg on the first day and 250 mg daily thereafter (this
dosing was used to be consistent with the commonly
prescribed Z-Pak). In the azithromycin arm, the placebo
was given at 500 mg once daily. Each subject enrolled
donated saliva, feces, and a skin swab on day 0 (day
prior to antibiotics), day 3 (3 days after initiation of anti-
biotics), day 7, week 8, and month 6. Of the 24 house-
holds enrolled, 5 of those households (Additional file 1:
Table S1) were lost to follow-up and did not provide
specimens at the month 6 time point. Each subject pro-
vided at least 3 ml of unstimulated saliva and a skin
swab from the volar surface of the forearm (the same
forearm surface was used for each sampling throughout
the study) [36–38]. Skin swabs were immediately placed
into a solution of 0.15 M NaCl and 0.1 % Tween 20 [37].
All subjects were encouraged to provide specimens in
the AM prior to breakfast and freeze them at −20 °C
prior to transporting on ice to the study site, where they
were frozen at −80 °C until use in this study. Exclusion
criteria included prior antibiotic use for 1 year prior to
the initiation of the study and preexisting medical condi-
tions such as diabetes, inflammatory bowel disease, and
organ transplantation that might result in significant im-
munosuppression. All subjects self-reported their health
status and were genetically unrelated.
Analysis of 16S rRNA
Genomic DNA was prepared from the saliva and skin
swabs of each subject and time point using the QIAGEN
QIAamp DNA MINI kit (QIAGEN). Each sample was
subjected to a bead beating step prior to nucleic acid ex-
traction using Lysing Matrix-B (MP Bio). Genomic DNA
was prepared from fecal samples using the QIAGEN
QIAamp DNA Stool Mini Kit (QIAGEN). We amplified
the bacterial 16S rRNA gene V1–V2 hypervariable re-
gion using the forward primer 8F (AGAGTTTGATCC
TGGCTCAG) fused with the Ion Torrent Adaptor A se-
quence and 1 of 70 unique 10 base pair barcodes and re-
verse primer 357R (CTGCTGCCTYCCGTA) fused with
the Ion Torrent Adaptor P1 from each donor and sam-
ple type [39]. PCR reactions were performed using Plat-
inum High Fidelity PCR SuperMix (Invitrogen) with the
following cycling parameters: 94 °C for 10 min, followed
by 30 cycles of 94 °C for 30 s, 53 °C for 30 s, 72 °C for
30 s, and a final elongation step of 72 °C for 10 min.
Resulting amplicons were purified on a 2 % agarose gel
stained with SYBR Safe (Invitrogen) using the MinElute
PCR Purification Kit (QIAGEN). Amplicons were further
purified with Ampure XP beads (Beckman-Coulter), and
molar equivalents were determined for each sample by
quantifying the amplicons using PicoGreen (Invitrogen)
using a plate reader. Samples were pooled into equal
molar proportions and sequenced on 316 chips using an
Ion Torrent PGM according to manufacturer’s instruc-
tions (Life Technologies) [40]. Resulting sequence reads
were removed from the analysis if they were <180 nucle-
otides or >500 nucleotides, had any barcode or primer
errors, contained any ambiguous characters, or con-
tained any stretch of >8 consecutive homopolymers. Se-
quences then were trimmed according to any site that
had a Phred score of less than 10 [41]. Sequences then
were assigned to their respective samples based on a 10-
nucleotide barcode sequence and were further processed
to remove reads that were greater than 3 standard devia-
tions from the mean read lengths in any specimen. Skin
reads were further processed to remove any reads
matching >97 % to a read from an Alphaproteobacteria
identified from the uninoculated control solution using
Ion Assist (www.thepridelaboratory.org).
We sequenced a minimum of 10,000 reads from each
sample and analyzed the sequence data using Quantita-
tive Insights Into Microbial Ecology (QIIME 1.5) [42].
We randomly sampled 8000 reads from each sample to
create subsamples that were used in each analysis using
Ion Assist (www.thepridelaboratory.org). Representative
OTUs from each set were chosen at a minimum se-
quence identity of 97 % using the QIIME script pick_o-
tus_through_otu_table, which uses the Greengenes
database [43]. PCOA was performed based on beta di-
versity using weighted UniFrac distances [33] using the
QIIME script beta_diversity_through_plots. The results
of the beta diversity distance matrices were used to de-
termine the weighted UniFrac distances between differ-
ent samples and sample groups. For each subject group,
we determined weighted UniFrac distances between each
subject pair within a household at each time point stud-
ied and compared those distances with between all pairs
of subjects who did not reside in the same household at
the same time points. Statistical significance was deter-
mined by the Mann Whitney U test using MaxStat Pro
(www.maxstat.de). This technique was utilized for deter-
mining the distances between household pairs who were
couples or roommates, household pairs who received
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amoxicillin and placebo, and household pairs who re-
ceived azithromycin and placebo. We also calculated the
distances between all household pairs receiving a specific
therapy at each time point studied. Statistical signifi-
cance was performed by comparing the mean distances
over time among household pairs using the Kruskal
Wallis test using MaxStat Pro. We utilized this tech-
nique to determine distances over time among house-
holds who received amoxicillin and azithromycin or that
contained couples or roommates.
Alpha diversity using the Shannon diversity index [44]
was determined using QIIME. The results were normal-
ized by body site to allow for direct comparisons of
changes in diversity between all the study subjects. We
used several different techniques for comparing diversity
between the study subjects. First, we calculated the
change in diversity for all subjects by comparing each
time point with their Shannon Index values on day 0.
For each household, we next compared the change in di-
versity between the subjects by subtracting the change
in diversity of the subject taking the placebo from the
change in diversity observed in the subject taking an-
tibiotics. Negative values indicated that there was a
reduction in diversity in the subjects taking antibiotics
compared to their housemate, and positive values in-
dicated that there was greater diversity in subjects
taking antibiotics compared to their housemate. The
change in diversity values were calculated for all
household pairs in different subject groups, and the
means and standard errors utilized to decipher trends.
Statistical differences in the means were determined
using the Mann Whitney U test. We utilized this
technique to decipher whether subject groups who re-
ceived amoxicillin and azithromycin had significant
differences in diversity between the housemates. The
next technique that we utilized was to determine
whether there were diversity reductions present inde-
pendent of housemates. We first normalized the
Shannon index values by body site and calculated the
change in diversity using day 0 as the index value.
We calculated this change in diversity among all sub-
jects who received amoxicillin, azithromycin, placebo,
or no therapy and utilized the means and standard
errors to help decipher trends in the data. Statistical
significance was determined by comparing each time
point between groups who received antibiotics with
those who received no therapy by the Mann Whitney
U test. The last technique utilized did not use day 0
as an index time point and instead compared the
change in diversity across each time point studied.
Statistical differences in alpha diversity were deter-
mined using the Mann Whitney U test for compari-
sons between each group taking antibiotics and those
of the controls.
We identified OTUs with significant changes in their
relative abundances by examining the OTU tables pro-
duced using QIIME. These OTU tables were normalized
and visually represented as heatmaps utilizing MEV 4.9
[45]. Significant differences (p < 0.01) in individual taxa
were determined by direct comparisons of each subject
taking antibiotics with their housemate. These compari-
sons were performed using the Rank Products algorithm
[46] typically used to identify differential expression in
response to perturbations. We reported only those taxa
that were significantly different between household
members and represented 1 % or greater of the taxa
present in the majority of individuals studied.
Additional files
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Additional file 2: This file contains Figures S1–S9. (PDF 1247 kb)
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